Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II infant study of GSK pneumococcal protein-containing vaccine formulations with routine hexavalent co-administration
2010-019730-27Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GSK 2189242A, 10-valent pneumococcal conjugate vaccine, pneumococcal 13-valent conjugate vaccine and pertussis filamentous haemagglutinin in pneumococcal disease and Haemophilus influenzae disease (4 arms), sponsored by GSK. Primary endpoints: Primary safety endpoint, Primary objective: non-inferiority for high fever and 1 more. Started Jun 2010; status: completed.
02
Drugs
GSK 2189242A10-valent pneumococcal conjugate vaccinepneumococcal 13-valent conjugate vaccinepertussis filamentous haemagglutinin
03
Conditions
pneumococcal diseaseHaemophilus influenzae disease
Beyond the preview
Go deeper on 2010-019730-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019730-27.